FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994183075> ?p ?o ?g. }

• W1994183075 endingPage "351" @default.
• W1994183075 startingPage "347" @default.
• W1994183075 abstract "Oral pseudomembranous candidiasis and mucositis were assessed in 39 patients receiving a total dose of 39–70 Gy radiotherapy for head and neck cancer. Mucositis was scored using the Radiation Therapy Oncology Group criteria, and oral candidiasis was diagnosed on the basis of clinical evaluation and quantitative laboratory findings. Radiation-induced mucositis was observed in 9/39 patients. Only 3/39 patients discontinued radiotherapy due to acute severe mucosal effects. Candidiasis (colony-forming units 35 to ≥60/lesion) associated with mucositis was diagnosed in 30/39 patients: the most frequent aetiology of the infection was Candida albicans (n = 23), followed by Candida glabrata (n = 3), Candida krusei (n = 2), Candida tropicalis (n = 1) and Candida kefyr (n = 1). Patients with confirmed oral pseudomembranous candidiasis were treated with either fluconazole 200 mg/day or itraconazole 200 mg/day for 2 weeks. Clinical improvement and concomitant negative Candida cultures (mycologic cure) were the criteria determining a response to antifungal treatment. Etest revealed very low voriconazole MICs (0.004–0.125 μg/ml) for all isolates, and fluconazole resistance for eight C. albicans strains (MIC > 64 μg/ml) and for the C. krusei isolates (MIC > 32 μg/ml). The same strains showed itraconazole susceptibility dose dependence (MIC 0.5 μg/ml). Despite the itraconazole susceptible dose dependent MIC readings, all patients with oral pseudomembranous candidiasis caused by these strains responded to antifungal treatment with 200 mg/day itraconazole. Oral mycologic surveillance of patients undergoing radiotherapy for head and neck malignancies and susceptibility testing of isolates may be indicated in cases with mucositis-associated confirmed oral pseudomembranous candidiasis to ensure prompt administration of targeted antifungal treatment. On the basis of the low MIC values found, clinical evaluation of voriconazole is indicated for management of oral pseudomembranous candidiasis refractory to other azoles." @default.
• W1994183075 created "2016-06-24" @default.
• W1994183075 creator A5004322327 @default.
• W1994183075 creator A5012981675 @default.
• W1994183075 creator A5019234582 @default.
• W1994183075 creator A5041469936 @default.
• W1994183075 creator A5045213649 @default.
• W1994183075 creator A5055611807 @default.
• W1994183075 creator A5058528342 @default.
• W1994183075 creator A5073373465 @default.
• W1994183075 creator A5074588010 @default.
• W1994183075 date "2004-12-01" @default.
• W1994183075 modified "2023-10-16" @default.
• W1994183075 title "Oral<i>Candida</i>isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment" @default.
• W1994183075 cites W1967547148 @default.
• W1994183075 cites W1970764087 @default.
• W1994183075 cites W1983858824 @default.
• W1994183075 cites W1985010021 @default.
• W1994183075 cites W1989991856 @default.
• W1994183075 cites W1995456274 @default.
• W1994183075 cites W1997903270 @default.
• W1994183075 cites W2000915744 @default.
• W1994183075 cites W2001731056 @default.
• W1994183075 cites W2002081119 @default.
• W1994183075 cites W2017817339 @default.
• W1994183075 cites W2019924096 @default.
• W1994183075 cites W2029360224 @default.
• W1994183075 cites W2042524149 @default.
• W1994183075 cites W2056536275 @default.
• W1994183075 cites W2069716936 @default.
• W1994183075 cites W2071431306 @default.
• W1994183075 cites W2072268052 @default.
• W1994183075 cites W2084581565 @default.
• W1994183075 cites W2095566116 @default.
• W1994183075 cites W2102572789 @default.
• W1994183075 cites W2103582483 @default.
• W1994183075 cites W2105204528 @default.
• W1994183075 cites W2113338279 @default.
• W1994183075 cites W2114403335 @default.
• W1994183075 cites W2132620894 @default.
• W1994183075 cites W2148279109 @default.
• W1994183075 cites W2152606525 @default.
• W1994183075 cites W2159732066 @default.
• W1994183075 cites W2160901787 @default.
• W1994183075 cites W2164291163 @default.
• W1994183075 cites W2167324847 @default.
• W1994183075 cites W2170379959 @default.
• W1994183075 cites W2314365205 @default.
• W1994183075 doi "https://doi.org/10.1111/j.1399-302x.2004.00165.x" @default.
• W1994183075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15491459" @default.
• W1994183075 hasPublicationYear "2004" @default.
• W1994183075 type Work @default.
• W1994183075 sameAs 1994183075 @default.
• W1994183075 citedByCount "87" @default.
• W1994183075 countsByYear W19941830752012 @default.
• W1994183075 countsByYear W19941830752013 @default.
• W1994183075 countsByYear W19941830752014 @default.
• W1994183075 countsByYear W19941830752015 @default.
• W1994183075 countsByYear W19941830752016 @default.
• W1994183075 countsByYear W19941830752017 @default.
• W1994183075 countsByYear W19941830752018 @default.
• W1994183075 countsByYear W19941830752019 @default.
• W1994183075 countsByYear W19941830752020 @default.
• W1994183075 countsByYear W19941830752021 @default.
• W1994183075 countsByYear W19941830752022 @default.
• W1994183075 countsByYear W19941830752023 @default.
• W1994183075 crossrefType "journal-article" @default.
• W1994183075 hasAuthorship W1994183075A5004322327 @default.
• W1994183075 hasAuthorship W1994183075A5012981675 @default.
• W1994183075 hasAuthorship W1994183075A5019234582 @default.
• W1994183075 hasAuthorship W1994183075A5041469936 @default.
• W1994183075 hasAuthorship W1994183075A5045213649 @default.
• W1994183075 hasAuthorship W1994183075A5055611807 @default.
• W1994183075 hasAuthorship W1994183075A5058528342 @default.
• W1994183075 hasAuthorship W1994183075A5073373465 @default.
• W1994183075 hasAuthorship W1994183075A5074588010 @default.
• W1994183075 hasConcept C121608353 @default.
• W1994183075 hasConcept C126322002 @default.
• W1994183075 hasConcept C141071460 @default.
• W1994183075 hasConcept C16005928 @default.
• W1994183075 hasConcept C2775835631 @default.
• W1994183075 hasConcept C2776530083 @default.
• W1994183075 hasConcept C2777071850 @default.
• W1994183075 hasConcept C2778496288 @default.
• W1994183075 hasConcept C2779548794 @default.
• W1994183075 hasConcept C2780651595 @default.
• W1994183075 hasConcept C2780670043 @default.
• W1994183075 hasConcept C2780690907 @default.
• W1994183075 hasConcept C2780908437 @default.
• W1994183075 hasConcept C2780917455 @default.
• W1994183075 hasConcept C2781425774 @default.
• W1994183075 hasConcept C509974204 @default.
• W1994183075 hasConcept C71924100 @default.
• W1994183075 hasConcept C86803240 @default.
• W1994183075 hasConcept C89423630 @default.
• W1994183075 hasConcept C90924648 @default.
• W1994183075 hasConceptScore W1994183075C121608353 @default.
• W1994183075 hasConceptScore W1994183075C126322002 @default.

• next